Metoprolol Succinate 25mg to Tartrate Conversion
When converting from metoprolol succinate 25 mg once daily to metoprolol tartrate, use 25 mg twice daily (50 mg total daily dose). This maintains equivalent beta-blockade while accounting for the different pharmacokinetic profiles of the two formulations.
Conversion Rationale
The FDA-approved labeling explicitly states that "when switching from immediate-release metoprolol to metoprolol succinate extended-release tablets, the same total daily dose of metoprolol succinate extended-release tablets should be used" 1. This principle applies bidirectionally.
Key conversion points:
- Metoprolol succinate 25 mg once daily = Metoprolol tartrate 25 mg twice daily
- The succinate formulation provides controlled release over 20 hours, maintaining relatively constant plasma levels 2
- The tartrate formulation requires twice-daily dosing to maintain therapeutic effect throughout the 24-hour period
Pharmacokinetic Differences
The two formulations differ substantially in their drug delivery:
- Metoprolol succinate (extended-release): Uses multiple-unit pellet system with zero-order release kinetics, providing steady plasma concentrations over 24 hours with lower peak concentrations and higher trough levels 3
- Metoprolol tartrate (immediate-release): Produces higher peak plasma concentrations but lower trough levels, requiring twice-daily administration for sustained beta-blockade 3
Studies demonstrate that metoprolol succinate achieves significantly higher plasma concentrations at 24 hours compared to once-daily tartrate dosing, while maintaining more consistent beta-1 blockade throughout the dosing interval 3.
Clinical Application by Indication
For Supraventricular Tachycardia
ACC/AHA/HRS guidelines list:
- Metoprolol tartrate: Initial dose 25 mg BID, maximum 200 mg BID 4, 5, 4
- Metoprolol succinate: Initial dose 50 mg QD, maximum 400 mg QD 4, 5, 4
For your 25 mg succinate dose: Convert to 25 mg tartrate twice daily, as this is the guideline-recommended starting dose for tartrate formulation.
For Post-MI and Heart Failure
ACCF/AHA STEMI guidelines recommend:
- Starting with metoprolol tartrate 25-50 mg every 6-12 hours, then transitioning to twice-daily tartrate dosing or daily succinate 6
- The equivalent daily succinate dose after stabilization 6
For Heart Failure
European and ACC/AHA heart failure guidelines specify:
- Metoprolol succinate CR: 12.5-25 mg once daily initially, target 200 mg daily 7
- Evidence-based mortality benefit demonstrated specifically with succinate formulation in MERIT-HF trial 8, 9
Important Clinical Caveats
Do not assume 1:1 mg equivalence for all doses. While 25 mg succinate converts to 25 mg tartrate BID at lower doses, the FDA label notes that "a 100-mg metoprolol controlled/extended-release tablet contains 95 mg of metoprolol succinate and is considered to have equivalent activity of 100 mg metoprolol tartrate" 2. This reflects the salt form difference (succinate vs tartrate), not the release mechanism.
Monitoring during conversion:
- Assess heart rate and blood pressure at trough (before next dose) with tartrate formulation
- The twice-daily tartrate dosing may show more variation in heart rate control throughout the day compared to once-daily succinate 3
- If converting in heart failure patients, maintain close monitoring for decompensation during the transition period
Formulation-specific evidence: The mortality benefit in heart failure was demonstrated specifically with metoprolol succinate (MERIT-HF), not with immediate-release tartrate 8, 9. The COMET trial showed metoprolol tartrate was inferior to carvedilol for mortality reduction in heart failure 10. If treating heart failure, strongly consider maintaining the succinate formulation rather than converting.